Jazz Pharmaceuticals has begun construction on a manufacturing facility in Ireland a month after acquiring a late stage narcoleptic compound.
The 55,000 sq ft facility has an expected completion date in 2016 and is located in Monksland, County Roscommon. With an estimated $60-68m (€45-50m) investment it is set to become the first manufacturing facility to be built by the company.
“This investment not only strengthens our international manufacturing capabilities, but importantly represents our commitment to expanding our presence in Ireland,” said Jazz CEO Bruce Cozadd.
The ground-breaking ceremony earlier this week was attended by Irish Prime Minister (Taoiseach) Enda Kenny and members of the Irish development agency, the IDA.
“Jazz Pharmaceuticals’ decision to build a manufacturing site in Ireland is testament to the excellent reputation Ireland has as a global location for biopharmaceutical development and manufacturing,” said Barry O’Leary, CEO IDA Ireland.
“This is a strategically important development for Jazz Pharmaceuticals and Ireland is well placed to support manufacturing for the company’s growing commercial portfolio.”
At full capacity, the facility will employ approximately 50 people.
Last month the firm acquired the rights to ADX-N05 - a compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy – from Aerial BioPharma for an upfront payment of $125m (€92m).
In-Pharmatechnologist.com contacted Jazz to find out if the new facility would support this drug but received no reply after numerous attempts by both telephone and email.